Rigel Pharmaceuticals, Inc. (RIGL) is flat to $3.11 in pre-market trading after it reported fiscal results for the fourth quarter.
In its quarterly report, the drug developer said it earned ($0.25) per share, above the ($0.27) per share analysts were expecting. Revenue rose 43.5% to $8.25 million, well above views for $2.5 million.
For the full-year 2014, Rigel reported contract revenues of $8.3 million and a net loss of $90.9 million, or $1.04 per share, compared to $7.2 million and a net loss of $89.0 million, or $1.02 per share, in 2013.
On valuation measures, Rigel Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 797,088 shares, trade with a t-12 P/S ratio of 45.65. Price/book is 1.79. The high Wall Street price target on the name is $10.00. Currently ticker boasts 1 ‘Buy’ endorsements, compared to 4 ’Holds’ and no ‘Sell’.
Profitability-wise, RIGL has a t-12 operating margin of (1,492%). The $273.03 million market cap company reported $143.16 million in cash – compared to $212 million yoy – versus $0 in debt in its most recent quarter.
RIGL currently prints a one year loss of about 10% and a year-to-date return of around 37%.
The chart below shows where the equity has traded over the last 52 weeks.
Rigel Pharmaceuticals Inc. is a clinical-stage drug development company that develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!